Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review

-



benign prostate :: Article Creator

High-power As Good As Low-power Thulium Laser Enucleation For Relieving Bladder Outlet Obstruction Due To BPH: Study

A significant study regarding the treatment of large-volume benign prostatic hyperplasia (BPH) revealed that low-power Thulium:YAG VapoEnucleation (ThuVEP) is just as effective and safe as its high-power counterpart. This finding published in the recent edition of World Journal of Urology could influence future treatment protocols and equipment choices for urological surgeries across...

A significant study regarding the treatment of large-volume benign prostatic hyperplasia (BPH) revealed that low-power Thulium:YAG VapoEnucleation (ThuVEP) is just as effective and safe as its high-power counterpart. This finding published in the recent edition of World Journal of Urology could influence future treatment protocols and equipment choices for urological surgeries across the world.

The study focused on a total of 80 patients who suffered from symptomatic benign prostatic obstruction (BPO) with prostate volumes exceeding 80 ml. They were randomly assigned into a group receiving low-power and the other group who received high-power ThuVEP treatment. The data analyzed over a 12-month follow-up period highlighted the perioperative and functional outcomes of these two surgical methods.

The key findings include the mean age of participants at 68 years and an average prostate volume of 112 cc, with no significant initial differences between the two groups. Surgical and enucleation times were slightly shorter in the low-power group, but the differences were not statistically significant. Both groups showed considerable improvements in prostate-related symptoms post-surgery which was measured by metrics like the quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax) and post-voiding residual urine (PVR).

Also, both surgical techniques demonstrated low complication rates which were similar across both the groups. This aspect is crucial as it suggests that the lower power setting does not compromise patient safety or the efficacy of the procedure. The findings of this study are pivotal for medical facilities considering the cost-effectiveness and accessibility of surgical equipment. Low-power ThuVEP not only requires less energy but might also lead to a lowered wear and tear on valuable medical instruments by potentially lowering operating costs without sacrificing clinical outcomes.

As the results of this study are critical, this could help the medical community prompt a reevaluation of current surgical standards and practices for treating large-volume BPH. This study adds valuable data to the existing pool of urological research and additionally opens the door for future studies to further refine and optimize the treatment of prostate enlargement for the best possible patient outcomes with consideration of economic factors in healthcare delivery.

Reference:

Abdelaziz, A. Y., Kamal, I., Abdelhakim, M. A., Abdelmohsen, M., Meshref, A., Naser, I., & Morsy, S. (2024). A prospective analysis of thulium laser enucleation in benign prostatic hyperplasia comparing low- and high-power approaches for prostates exceeding 80 g. In World Journal of Urology (Vol. 42, Issue 1). Springer Science and Business Media LLC. Https://doi.Org/10.1007/s00345-024-04901-w


FDA Clears Profound Medical's AI Model For Treating Prostate Cancer

[author: Sumaia Tabassum]

Profound Medical (Nasdaq: PROF) has received FDA 510(k) clearance for its second AI model aimed at treating prostate cancer. Profound Medical is a Toronto-based company, which specializes in developing and marketing customizable, non-invasive therapies for tissue ablation. The newly cleared AI model, called the Contouring Assistant, complements Profound Medical's TULSA-Pro system, which is designed for transurethral ultrasound ablation (TULSA) procedures.

The TULSA procedure offers a treatment option for various stages of prostate cancer, including low, intermediate, and high-risk cases, as well as for patients with both prostate cancer and benign prostatic hyperplasia (BPH), men with only BPH, and those requiring salvage therapy for radio-recurrent localized prostate cancer. This technology utilizes real-time magnetic resonance (MR) guidance to precisely target and ablate diseased tissue while preserving urinary continence and sexual function. A single session of treatment can typically be completed in just a few hours.

The Contouring Assistant AI module employs machine learning to assist in segmenting the prostate by delineating the prostate and target ablation volume.

Looking ahead, Profound Medical is working on its next TULSA-AI module, TULSA BPH, with more information expected later in 2024. Arun Menawat, CEO and Chair of Profound Medical, views the clearance of the Contouring Assistant as an important milestone in fulfilling the company's commitment to improving the TULSA treatment experience for both urologists and their patients. He anticipates that the new AI module will not only enhance urologists' confidence in treatment designs but also significantly increase their procedural efficiency.


Fox Chase-Temple Urologic Institute Is Advancing Treatment For Benign Prostatic Hyperplasia

Fox Chase-Temple Urologic Institute is advancing treatment for benign prostatic hyperplasia through new and minimally invasive techniques.

PHILADELPHIA (WPVI) -- Benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland, is the most common benign tumor found in men.

BPH produces symptoms by obstructing the flow of urine through the urethra.

Symptoms related to BPH are present in about one in four men by age 55, and in half of 75-year-old men.

However, treatment is only necessary if symptoms become bothersome.

The Fox Chase-Temple Urologic Institute is advancing treatment for benign prostatic hyperplasia through new and minimally invasive techniques.

Doctor Steven Sterious, a Surgeon at Fox Chase-Temple Urologic Institute, explains what benign prostatic hyperplasia is and how common it is.

Dr. Sterious also discusses what symptoms to look out for and treatment options available.

Dr. Steve Sterious is one of the pioneering surgeons to offer a new minimally invasive treatment for enlarged prostate called Aquablation Therapy, which uses waterjets to remove the unhealthy tissue.

Dr. Sterious has been involved in the research of this new treatment and is now offering this to Philadelphia residents.

Visit TempleHealth.Org to learn more.

Copyright © 2024 WPVI-TV. All Rights Reserved.





Comments

Post a Comment

Popular posts from this blog

Cancer Glossary | Definitions & Phonetic Pronunciations

-
Image
mucositis treatment :: Article Creator Vitamins By Condition Learn about User Reviews and read IMPORTANT information about user generated content Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you. This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source i...
Read more

Sentinel lymph node biopsy: What cancer patients should know

-
Image
cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
Read more

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

-
Image
Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with  BRCA1/2  or  ATM  alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the  BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or  RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...
Read more